证券代码：300109 证券简称：新开源 公告编号：2025-024 博爱新开源医疗科技集团股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况。 2、本次股东大会不涉及变更前次股东大会决议。 3、本次股东大会采用现场投票、网络投票相结合的方式。 一、会议召开和出席情况 （一）会议召开情况 2025 年 4 月 18 日，博爱新开源医疗科技集团股份有限公司（以下简称"公 司"）董事会以公告形式向全体股东发出召开 2024 年年度股东大会的通知。本次 会议以现场、网络相结合的方式于 2025 年 5 月 30 日 14:00 在河南省博爱县文化 路（东段）1888 号公司三楼会议室召开。 本次股东大会由公司董事会召集，董事长张军政先生主持，公司部分董事、 监事、高级管理人员及公司聘请的见证律师列席了会议。会议的召集、召开与表 决程序符合国家有关法律法规、部门规章和《公司章程》等规范性文件的规定。 （二）会议出席情况 1、股东出席的总体情况： 通过现场和网络投票的股 ...

Group 1 - The A-share market closed positively, with the Sci-Tech 50 Index ETF (588870) rising by 1.71%, ending a seven-day decline, and achieving a turnover rate of over 14%, the highest among its peers [1] - The Sci-Tech 50 Index ETF (588870) has seen a premium of 0.19% at closing and has recorded net inflows for ten consecutive days, with a net inflow rate of 112% over the past 60 days [1] - Major stocks within the Sci-Tech 50 Index ETF saw gains, including Junshi Biosciences up over 7%, Kingsoft Office and Zhongwei Company up over 3%, and others showing positive performance [3] Group 2 - CITIC Securities forecasts that AI will remain a key investment theme in the second half of 2025, driven by continuous advancements in large models and the exploration of applications by Chinese tech companies [4] - The AI industry in China has gained sustained attention, particularly following the impact of DeepSeek, with expectations for the release of DeepSeek R2 and GPT-5 in the latter half of the year [4] - Investment opportunities are anticipated in the expansion of the AI ecosystem and its application across various sectors [4] Group 3 - The performance of foundational models is improving rapidly, with a notable increase in cost-effectiveness expected in the first half of 2025, driven by advancements in model capabilities and reduced pricing [5] - The infrastructure for computing power remains robust, with significant capital expenditures from major cloud service providers in North America and China, indicating strong market demand [6] - Domestic chip manufacturers are expected to accelerate production due to restrictions on high-end chip access from the U.S., leading to a focus on developing advanced manufacturing capabilities [6] Group 4 - The Sci-Tech 50 Index ETF (588870) has outperformed its peers since its launch on January 27, 2025, with a 3.05% increase compared to the index's 1.18% [7][8] - The ETF tracks the top 50 stocks in the Sci-Tech sector, covering various industries such as electronics, pharmaceuticals, and computing, with low management and custody fees [7]

1、会议届次：2024年年度股东大会 证券代码：300109 证券简称：新开源 公告编号：2025-023 博爱新开源医疗科技集团股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《公司章程》有关规定，经博爱新开源医 疗科技集团股份有限公司（以下简称"公司"）第五届董事会第十五次会议审议通 过，决定召开 2024 年年度股东大会。现将有关事项通知如下： 一、召开会议的基本情况 2、召集人：公司董事会 3、会议召开的合法、合规性：经公司第五届董事会第十五次会议审议通过， 决定召开2024年年度股东大会，召集的程序符合《深圳证券交易所创业板股票上 市规则》等相关法律法规和《公司章程》的规定。 4、会议召开时间： 现场会议时间：2025年5月30日（星期五）下午14:00 网络投票时间：2025年5月30日 其中，通过深圳证券交易所交易系统进行网络投票的时间为2025年5月30日 上午9:15-9:25，9:30-11:30，下午13:00-15:00；通过深圳证券交易所互联网系统 投 ...

关于参加河南辖区上市公司 2025 年投资者网上集体 接待日活动的公告 证券代码：300109 证券简称：新开源 公告编号：2025-022 博爱新开源医疗科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强投资者的互动交流，博爱新开源医疗科技集团股份有限公司定 于 2025 年 5 月 22 日（周四）15:25-16:55 参加在全景网举办的河南辖区上市公 司 2025 年投资者网上集体接待日活动，本次活动将采用网络远程的方式举行， 投资者可登录"全景·路演天下"（http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：董事会秘书邢小亮先生，财务总监 刘爱民先生，证券事务代表张燕兰女士（如有特殊情况，参会人员将可能进行调 整），欢迎广大投资者积极参与。 博爱新开源医疗科技集团股份有限公司 董事会 2025 年 5 月 19 日 特此公告 ...

Financial Performance - In 2024, the company achieved operating revenue of 1,606.32 million yuan, a year-on-year increase of 1.45% [2] - The net profit attributable to the parent company was 349.68 million yuan, a decrease of 29.07% compared to the previous year [2] - Earnings per share were 0.73 yuan, down 30.48% year-on-year, primarily due to a decline in gross profit from high polymer products [3] - In Q1 2025, operating revenue was 324.86 million yuan, a decrease of 17.69% year-on-year [3] - The net profit attributable to the parent company for Q1 2025 was 80.42 million yuan, down 33.75% year-on-year, with earnings per share at 0.17 yuan, a decrease of 32.00% [3] Product Applications - PVP is used in the new energy sector as a dispersant for carbon nanotubes and in solid-state batteries for material dispersion and interface optimization [3] - In 2024, the expected shipment volume for new energy applications is over 3,000 tons, with a projected increase in 2025 [3] - PVP's application in electronic skin focuses on material modification and conductive network construction, with no large-scale shipments currently [4] Pricing and Market Impact - PVP prices have significantly decreased compared to the previous two years and are currently stabilizing [4] - The company anticipates an increase in average product prices as the proportion of high-end products rises [4] - Approximately 50% of PVP exports are to Europe, the Middle East, Southeast Asia, and India, with exports to the U.S. accounting for only 3%-5% [5] Product Overview - Euriz is a copolymer of vinyl ether/maleic anhydride, known for its linear molecular structure and good chemical stability [5] - In 2024, Euriz sales are expected to reach about 1,500 tons, with approximately 90% for export and a high unit price [5] - The estimated shipment volume for Euriz in 2025 is over 2,000 tons, with a gross profit margin of 60-70% [5]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xin Kai Yuan, which closed at 16.82 yuan on May 12, with a 6.25% increase, resulting in a rolling PE ratio of 26.41, the lowest in 25 days, and a total market capitalization of 8.153 billion yuan [1] - Xin Kai Yuan ranks 77th in the chemical products industry, which has an average PE ratio of 43.30 and a median of 39.16 [1][2] - The company experienced a net inflow of 41.4149 million yuan in main funds on May 12, with a total inflow of 85.9945 million yuan over the past five days [1] Group 2 - Xin Kai Yuan's main business focuses on fine chemicals and precision medicine, with key products including PVPK30, PVP-I, and various diagnostic services [1] - The latest financial results for Q1 2025 show that the company achieved an operating income of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit of 80.4203 million yuan, down 33.75%, with a gross profit margin of 44.07% [1]

最新一期业绩显示，2025年一季报，公司实现营业收入3.25亿元，同比-17.69%；净利润8042.03万元， 同比-33.75%，销售毛利率44.07%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)76新开源23.5520.791.9672.71亿行业平均 53.5558.002.8575.43亿行业中值37.2338.092.2537.97亿1宏柏新材-5269.4152.781.7734.29亿2北化股 份-2017.8798.311.9454.57亿3安诺其-1284.26-1284.262.4060.95亿4锦鸡股份-726.89212.691.9833.71亿5渝 三峡A-605.83-63.641.7722.16亿6富淼科技-398.64-398.641.3918.55亿7信德新材-254.72-107.271.3235.45亿 8凯美特气-151.62-258.203.2966.13亿9达威股份-128.16-128.161.6014.67亿10ST联 创-125.76340.482.2743.29亿11康鹏科技-125.08-96.151.7047.63亿 来源：金融界 4月2 ...

Core Viewpoint - New Kaineng's net profit for 2024 is expected to decline by approximately 30% due to decreased gross margins in PVP series products, with the medical services segment shrinking to less than 10% of total revenue [1][2][3] Financial Performance - In 2024, the company achieved operating revenue of 1.606 billion yuan, a year-on-year increase of 1.45%, while net profit attributable to shareholders was 350 million yuan, a decrease of 29.07% [1] - The net profit excluding non-recurring gains and losses was 361 million yuan, down 25.76% year-on-year [1] - For Q1 2025, the company reported revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit of 80 million yuan, down 33.75% [1] Product Performance - The gross margin for the fine chemical business in 2024 was 47.80%, a decline of 11.82 percentage points year-on-year [1] - The gross margins for specific products in the PVP series were as follows: PVPK30 at 38.04% (down 15.65 percentage points), PVP-I at 31.88% (down 7.8 percentage points), Eurozi series at 63.37% (down 12.22 percentage points), and PVP series at 53.16% (down 10.01 percentage points) [1] Cash Flow and Sales - The company's operating cash flow for the previous year was approximately 256 million yuan, a decrease of 47.56% year-on-year, primarily due to reduced cash received from sales [2] - Sales revenue from the PVP series products was 748 million yuan, with a year-on-year increase of 31%, while the top-selling product PVPK30 generated revenue of 492 million yuan, a decrease of 10.77% [2] Medical Services Segment - The medical services segment has seen a significant decline in revenue contribution, dropping from 53.18% in 2019 to 9.63% in 2024 [2] - Corresponding gross profit from the medical services segment also decreased from 61.84% in 2019 to 7.99% in 2024 [2] Impairment and Acquisitions - In 2024, the company recognized goodwill impairment of 45 million yuan, with approximately 23 million yuan and 22 million yuan allocated to subsidiaries Sanji Biological and Jingneng Biological, respectively [2] - The company previously acquired three firms in the medical services sector for a total of 543 million yuan, with significant premium rates at the time of acquisition [2]

Core Viewpoint - The company has reported its annual financial results, highlighting its main business areas in fine chemicals and precision medicine, along with a proposed cash dividend distribution to shareholders [1][25]. Company Overview - The company specializes in fine chemicals and precision medicine, being the first in China to focus on the production, research, and sales of PVP series products and PVME/MA series products [5][25]. - The main products include PVP, which is widely used in pharmaceuticals, food processing, cosmetics, new energy, environmental water treatment, and other industrial fields [6][20]. Financial Highlights - The company has proposed a cash dividend of 2.5 yuan per 10 shares (including tax) based on a total of 484,700,005 shares, with no stock bonus [4][31]. - The company has undergone a change in its auditing firm to Zhongqin Wanxin Certified Public Accountants [3]. Business Applications - PVP products are utilized in various sectors: - **Pharmaceuticals**: Used as binders, stabilizers, and release agents in drug formulations [6][7]. - **Food Processing**: Acts as a clarifying agent and stabilizer [8][9]. - **Cosmetics**: Functions as a thickening agent and moisture-retaining agent [10][11]. - **New Energy**: Serves as a dispersant in lithium batteries and enhances photovoltaic cell efficiency [12][13]. - **Environmental Treatment**: Used in membrane materials and as inhibitors in gas transportation [14][15]. - **Other Industries**: Improves the performance of coatings, inks, textiles, and paper [16][18][19]. Strategic Developments - The company has approved investments in two entities, increasing its stake in Huadao Biological and Zhongqi Huiyun Technology [29]. - The company is focusing on expanding its precision medicine services, leveraging its technology in equipment, reagents, and medical services [24].

证券代码：300109 证券简称：新开源 公告编号：2025-015 博爱新开源医疗科技集团股份有限公司 关于 2025 年度开展外汇期权及结构性存款业务的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日分别召开第五届董事会第十五次会议、第五届监事会第十一次会议审议通 过《关于 2025 年度开展外汇期权及结构性存款业务的议案》，同意公司以不超 过 1,000 万美元或等值外币的自有资金开展外汇期权业务，及同意公司以不超过 3 亿元人民币开展结构性存款业务，上述业务授权期限自本次董事会审议通过之 后的十二个月内。在授权期限内，资金可以循环滚动使用，若使用投资获取的收 益进行再投资，期限内任一时点的金额不应超过已审议额度。具体内容如下： 一、投资情况概述 1、投资目的 在充分保障公司日常经营的资金需求，不影响公司正常经营及发展的情况 下，为提高资金使用效率，有效规避和防范汇率风险，减少汇率波动对公司经营 的影响，公司拟开展外汇期权业务；为提升闲置自有资金使用效率，增加财务收 ...